Core Insights - Acurx Pharmaceuticals has been granted a new patent in India for DNA Polymerase IIIC Inhibitors, adding to its portfolio of patents aimed at protecting its antimicrobial technologies [1][2] - The company is advancing its lead product candidate, ibezapolstat, which is Phase 3-ready for the treatment of C. difficile Infection, and is also developing second-generation compounds for various gram-positive bacterial infections [2][3] Patent Developments - The newly granted Indian patent is part of a series of patents that Acurx has secured, including three U.S. patents, one Israeli patent, and one Japanese patent, all related to the ACX-375C program [1][3] - The patent covers compositions-of-matter for DNA Polymerase IIIC Inhibitors, which are crucial for the company's proprietary technologies in antimicrobials [1] Product Pipeline - Acurx's R&D pipeline focuses on antibiotics targeting gram-positive bacteria, including C. difficile, MRSA, VRE, DRSP, and anthrax [3] - The company plans to initiate international clinical trials for ibezapolstat as soon as possible, with a preclinical pipeline also in development for treating ABSSSI and inhaled anthrax [3]
Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors